EA201171397A1 - Иммунологическое нацеливание на патологические тау-протеины - Google Patents
Иммунологическое нацеливание на патологические тау-протеиныInfo
- Publication number
- EA201171397A1 EA201171397A1 EA201171397A EA201171397A EA201171397A1 EA 201171397 A1 EA201171397 A1 EA 201171397A1 EA 201171397 A EA201171397 A EA 201171397A EA 201171397 A EA201171397 A EA 201171397A EA 201171397 A1 EA201171397 A1 EA 201171397A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- patient
- immunological
- proteins
- defining
- pathological tau
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Изобретение относится к способам и композициям для лечения, предотвращения и диагностирования болезни Альцгеймера и других таупатий у пациента путем введения иммуногенного тау-пептида или антитела, распознающего иммуногенный тау-эпитоп, в условиях, эффективных для лечения, предупреждения или диагностирования болезни Альцгеймера или других таупатий. Также описаны способы ускорения выведения скоплений из мозга пациента и замедления прогрессирования связанного с тау-патологией поведенческого фенотипа пациента.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18589509P | 2009-06-10 | 2009-06-10 | |
PCT/US2010/038184 WO2010144711A2 (en) | 2009-06-10 | 2010-06-10 | Immunological targeting of pathological tau proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201171397A1 true EA201171397A1 (ru) | 2012-05-30 |
EA032675B1 EA032675B1 (ru) | 2019-07-31 |
Family
ID=43306616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201171397A EA032675B1 (ru) | 2009-06-10 | 2010-06-10 | Способ и композиции для лечения болезни альцгеймера и других таупатий |
Country Status (7)
Country | Link |
---|---|
US (4) | US8748386B2 (ru) |
EP (3) | EP2440234A4 (ru) |
JP (6) | JP5917394B2 (ru) |
CN (2) | CN106390107B (ru) |
CA (2) | CA2765099A1 (ru) |
EA (1) | EA032675B1 (ru) |
WO (1) | WO2010144711A2 (ru) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090142766A1 (en) * | 2007-11-09 | 2009-06-04 | Washington University In St. Louis | Methods for measuring the metabolism of cns derived biomolecules in vivo |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
CA2765099A1 (en) * | 2009-06-10 | 2010-12-16 | New York University | Phosphorylated tau peptide for use in the treatment of tauopathy |
CN102596236B (zh) * | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
CN103502272B (zh) * | 2010-10-07 | 2016-06-15 | Ac免疫有限公司 | 识别Tau的磷酸化特异抗体 |
AU2013205313B2 (en) * | 2010-10-07 | 2016-05-19 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
SI2627672T1 (sl) | 2010-10-11 | 2018-10-30 | Biogen International Neuroscience Gmbh | Človeška protitelesa anti-tau |
CA2826286C (en) * | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
US8697076B2 (en) * | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
GB201111361D0 (en) * | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
AU2012311234B2 (en) | 2011-09-19 | 2017-09-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease |
EP3135689B1 (en) | 2011-10-07 | 2018-12-19 | AC Immune S.A. | Phosphospecific antibodies recognising tau |
WO2013059786A1 (en) * | 2011-10-21 | 2013-04-25 | The Ohio State University | Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease |
MY186066A (en) * | 2011-12-20 | 2021-06-18 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
RU2644242C2 (ru) | 2012-04-05 | 2018-02-08 | Ац Иммуне С.А. | Гуманизированное тау-антитело |
US20150183854A1 (en) | 2012-05-31 | 2015-07-02 | Teijin Pharma Limited | Therapeutic agent or prophylactic agent for dementia |
RU2018132044A (ru) * | 2012-07-03 | 2018-10-19 | Вашингтон Юниверсити | Антитела против тау |
BR112015003326A2 (pt) | 2012-08-16 | 2017-07-04 | Ipierian Inc | métodos de tratamento de uma tauopatia |
US20140056901A1 (en) * | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
CA2885924C (en) * | 2012-08-21 | 2022-12-13 | Institute For Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein |
US9200068B2 (en) * | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
PT2935326T (pt) * | 2012-12-21 | 2020-09-14 | Biogen Ma Inc | Anticorpos anti-tau humanos |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
PE20152004A1 (es) * | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
US9598485B2 (en) | 2013-03-15 | 2017-03-21 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
US20160355573A1 (en) * | 2013-09-05 | 2016-12-08 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
EP3074420A2 (en) * | 2013-11-27 | 2016-10-05 | Ipierian, Inc. | Methods of treating a tauopathy |
WO2015089375A1 (en) | 2013-12-13 | 2015-06-18 | The General Hospital Corporation | Soluble high molecular weight (hmw) tau species and applications thereof |
WO2015120364A1 (en) * | 2014-02-10 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antibodies that bind to human tau and assay for quantifying human tau using the antibodies |
JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン,インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
EP3486256A3 (en) * | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
US10830775B2 (en) | 2014-09-30 | 2020-11-10 | Washington University | Tau kinetic measurements |
JP6979577B2 (ja) | 2015-02-20 | 2021-12-15 | アミロニクス アクティエボラーグ | アルツハイマーaベータペプチド結合ポリペプチド |
TWI669314B (zh) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | 針對tau之抗體及其用途 |
US20180050097A1 (en) * | 2015-03-25 | 2018-02-22 | Stc. Unm | Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
CN107849105B (zh) | 2015-07-06 | 2021-09-17 | Ucb生物制药有限责任公司 | Tau结合抗体 |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
EP3334761B1 (en) * | 2015-08-13 | 2023-07-19 | New York University | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
WO2017027685A2 (en) | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
EP3366770A4 (en) * | 2015-10-22 | 2019-04-24 | Immunotherapy Development Inc. | DNA VACCINE AGAINST AMYLOID BETA AND TAU |
HUE037916T2 (hu) | 2015-11-20 | 2018-09-28 | Geroa Diagnostics S L | Laktoferrin Alzheimer-kór diagnózisában és prognózisában történõ alkalmazására |
WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
CU24537B1 (es) | 2016-05-02 | 2021-07-02 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6 |
KR102506091B1 (ko) | 2016-05-02 | 2023-03-07 | 프로테나 바이오사이언시즈 리미티드 | 타우 면역요법 |
US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
TN2018000419A1 (en) | 2016-07-12 | 2020-06-15 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof. |
EP3496750A2 (en) | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
WO2018078038A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
EP3532053A1 (en) | 2016-10-28 | 2019-09-04 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
WO2018106889A1 (en) * | 2016-12-09 | 2018-06-14 | Cogwellin L.L.C. | Diagnosis of alzheimer's disease |
US11001615B2 (en) * | 2016-12-21 | 2021-05-11 | Adel Inc. | Mutated tau protein fragment and use thereof |
WO2018127519A1 (en) | 2017-01-04 | 2018-07-12 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
CN110520440A (zh) * | 2017-02-17 | 2019-11-29 | 戴纳立制药公司 | 抗τ抗体及其使用方法 |
JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
EP3601325B1 (en) * | 2017-03-28 | 2023-07-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New tau species |
AU2018263935A1 (en) | 2017-05-02 | 2019-12-19 | Prothena Biosciences Limited | Antibodies recognizing tau |
TW202340244A (zh) | 2017-10-16 | 2023-10-16 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
IL302108A (en) | 2017-10-25 | 2023-06-01 | Ac Immune Sa | Preparations of phosphorylated tau peptides and uses thereof |
EP3700558A4 (en) | 2017-10-27 | 2022-03-09 | United Neuroscience | TAU PEPTIDE IMMUNOGEN CONSTRUCTS |
HUE057202T2 (hu) | 2017-12-14 | 2022-04-28 | H Lundbeck As | Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával |
AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
WO2019171258A1 (en) * | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
CN110548135B (zh) * | 2018-05-31 | 2023-06-06 | 长春百克生物科技股份公司 | 磷酸化多肽抗原疫苗及其制备方法和应用 |
CA3107788A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
US20220273779A1 (en) * | 2018-11-19 | 2022-09-01 | The Board Of Regents Of The University Of Texas System | Tau peptide antigens and antibodies binding thereto for the treatment of tauopathies |
WO2020123492A1 (en) * | 2018-12-10 | 2020-06-18 | New York University | Monoclonal antibodies targeting c-terminal region of phosphorylated tau |
CN111323597A (zh) * | 2018-12-14 | 2020-06-23 | 陈志成 | 用于检测受试者中mci和/或ad的方法、试剂盒及筛选化合物的方法 |
CN113710269A (zh) * | 2019-02-08 | 2021-11-26 | Ac免疫有限公司 | 磷酸化Tau肽疫苗的安全施用方法 |
JP2022524588A (ja) | 2019-03-03 | 2022-05-09 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
US11155609B2 (en) | 2019-04-05 | 2021-10-26 | TauC3 Biologies Limited | Anti-TAUC3 antibodies and uses thereof |
WO2020219646A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceuticals, Inc. | Heterologous administration of tau vaccines |
GB201909393D0 (en) | 2019-06-28 | 2019-08-14 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
CN110317814A (zh) * | 2019-07-19 | 2019-10-11 | 莫丁丁 | β-淀粉样蛋白环状核糖核酸、多肽及其应用 |
AU2020345110A1 (en) | 2019-09-09 | 2022-03-24 | Axon Neuroscience Se | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment |
CN110684122B (zh) * | 2019-10-29 | 2021-03-02 | 中国人民解放军军事科学院军事医学研究院 | 重组Tau表位嵌合多聚体抗原、其制备方法和应用 |
AU2021297873A1 (en) | 2020-06-25 | 2023-02-09 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
JPWO2022054795A1 (ru) * | 2020-09-08 | 2022-03-17 | ||
AU2022328342A1 (en) * | 2021-08-12 | 2024-02-22 | Ac Immune Sa | Liposomes containing phosphorylated tau peptides for inducing sustained immune responses |
WO2024005008A1 (ja) * | 2022-06-28 | 2024-01-04 | 大塚製薬株式会社 | シヌクレイノパチーを判定するための方法 |
CN116948025B (zh) * | 2023-09-14 | 2024-04-02 | 北京凯祥弘康生物科技有限公司 | 一种抗Tau蛋白的抗体 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
EP0497922B1 (en) | 1989-10-24 | 2002-01-30 | Chiron Corporation | Infective protein delivery system |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
JP2916297B2 (ja) * | 1991-02-25 | 1999-07-05 | 三菱化学株式会社 | ホスホペプチド |
EP0600951A4 (en) | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
FR2681786A1 (fr) | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
JP3909084B2 (ja) | 1991-10-25 | 2007-04-25 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | 微小管結合タンパク質タウに対するモノクローナル抗体 |
CA2125298A1 (en) * | 1991-12-06 | 1993-06-10 | Eva-Maria Mandelkow | Tools for the diagnosis and treatment of alzheimer's disease |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US6010913A (en) * | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
JPH08512056A (ja) | 1993-06-30 | 1996-12-17 | ジェネンテク・インコーポレイテッド | リポソームの製造法 |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
DE69534166T2 (de) | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | Rekombinanter adenovirus und methoden zu dessen verwendung |
US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
WO1997020575A1 (en) | 1995-12-08 | 1997-06-12 | The University Of Alabama At Birmingham Research Foundation | Targeted adenovirus vectors |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
EP1284998B1 (en) | 2000-05-22 | 2004-12-29 | New York University | Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits |
EP1347731B1 (en) | 2000-11-02 | 2007-04-25 | Cornell Research Foundation, Inc. | In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease |
AU2002338446A1 (en) | 2001-01-23 | 2002-11-05 | University Of Rochester Medical Center | Methods of producing or identifying intrabodies in eukaryotic cells |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
US6821504B2 (en) | 2001-05-23 | 2004-11-23 | New York University | Detection of alzheimer's amyloid by magnetic resonance imaging |
US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
AU2002345843A1 (en) | 2001-06-22 | 2003-01-08 | Panacea Pharmaceuticals, Inc. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
WO2003045128A2 (en) | 2001-11-21 | 2003-06-05 | New York University | SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO |
GB0226727D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
US20040247661A1 (en) | 2002-07-03 | 2004-12-09 | Dov Michaeli | Liposomal vaccine |
WO2004083431A1 (ja) * | 2003-03-19 | 2004-09-30 | Zoegene Corporation | 転写反応を調節するタンパク質のスクリーニング方法および活性測定方法 |
US7632816B2 (en) | 2003-03-28 | 2009-12-15 | New York University | Treatment of Alzheimer amyloid deposition |
US8685718B2 (en) | 2003-05-20 | 2014-04-01 | New York University | Mucosal immunization to prevent prion infection |
JP2008540417A (ja) * | 2005-05-05 | 2008-11-20 | メルク エンド カムパニー インコーポレーテッド | ペプチドコンジュゲート組成物およびアルツハイマー病の予防および治療のための方法 |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
EP2077863A4 (en) | 2006-10-31 | 2010-10-06 | Domantis Ltd | intrabodies |
US20080220449A1 (en) * | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
SI2408807T1 (sl) * | 2009-03-18 | 2021-11-30 | Ac Immune Sa | Postopek za terapevtsko uporabo |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
CA2765099A1 (en) * | 2009-06-10 | 2010-12-16 | New York University | Phosphorylated tau peptide for use in the treatment of tauopathy |
CN102596236B (zh) * | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
-
2010
- 2010-06-10 CA CA2765099A patent/CA2765099A1/en not_active Abandoned
- 2010-06-10 US US12/813,297 patent/US8748386B2/en active Active
- 2010-06-10 CA CA3120504A patent/CA3120504A1/en active Pending
- 2010-06-10 CN CN201610638487.5A patent/CN106390107B/zh active Active
- 2010-06-10 EA EA201171397A patent/EA032675B1/ru not_active IP Right Cessation
- 2010-06-10 CN CN201080036213.XA patent/CN102596221B/zh active Active
- 2010-06-10 EP EP10786852.3A patent/EP2440234A4/en not_active Ceased
- 2010-06-10 WO PCT/US2010/038184 patent/WO2010144711A2/en active Application Filing
- 2010-06-10 EP EP17197129.4A patent/EP3329932A1/en not_active Withdrawn
- 2010-06-10 JP JP2012515141A patent/JP5917394B2/ja active Active
- 2010-06-10 EP EP23159184.3A patent/EP4218794A3/en active Pending
-
2014
- 2014-04-25 US US14/261,506 patent/US20140302046A1/en not_active Abandoned
-
2015
- 2015-11-26 JP JP2015230384A patent/JP6174667B2/ja active Active
-
2017
- 2017-01-06 US US15/400,533 patent/US20170183400A1/en not_active Abandoned
- 2017-07-06 JP JP2017132595A patent/JP6518727B2/ja active Active
-
2019
- 2019-04-22 JP JP2019080694A patent/JP6795649B2/ja active Active
-
2020
- 2020-11-05 US US17/090,359 patent/US11787854B2/en active Active
- 2020-11-12 JP JP2020188406A patent/JP7229980B2/ja active Active
-
2022
- 2022-10-04 JP JP2022159988A patent/JP2022180615A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2010144711A3 (en) | 2011-05-26 |
CN102596221B (zh) | 2019-06-04 |
EP4218794A3 (en) | 2023-09-13 |
CN102596221A (zh) | 2012-07-18 |
EP2440234A4 (en) | 2013-11-06 |
US20210061894A1 (en) | 2021-03-04 |
CA3120504A1 (en) | 2010-12-16 |
JP2016094426A (ja) | 2016-05-26 |
EP2440234A2 (en) | 2012-04-18 |
CN106390107A (zh) | 2017-02-15 |
EA032675B1 (ru) | 2019-07-31 |
US20140302046A1 (en) | 2014-10-09 |
JP5917394B2 (ja) | 2016-05-11 |
JP7229980B2 (ja) | 2023-02-28 |
JP2021042219A (ja) | 2021-03-18 |
US20170183400A1 (en) | 2017-06-29 |
JP2012530055A (ja) | 2012-11-29 |
JP6795649B2 (ja) | 2020-12-02 |
JP6518727B2 (ja) | 2019-05-22 |
JP2019163268A (ja) | 2019-09-26 |
JP6174667B2 (ja) | 2017-08-02 |
WO2010144711A2 (en) | 2010-12-16 |
US11787854B2 (en) | 2023-10-17 |
CN106390107B (zh) | 2019-12-31 |
CA2765099A1 (en) | 2010-12-16 |
JP2017193571A (ja) | 2017-10-26 |
EP4218794A2 (en) | 2023-08-02 |
JP2022180615A (ja) | 2022-12-06 |
EP3329932A1 (en) | 2018-06-06 |
US8748386B2 (en) | 2014-06-10 |
US20100316564A1 (en) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201171397A1 (ru) | Иммунологическое нацеливание на патологические тау-протеины | |
MY164376A (en) | Phosphospecific antibodies recognizing tau | |
MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
CR20150016A (es) | Anticuerpo monoclonal | |
MX2011010353A (es) | Composicion farmaceutica. | |
EA201270813A1 (ru) | АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ | |
BR112014006376A2 (pt) | terapia baseada em proteínas e diagnóstico de patologia mediada por tau em doença de alzheimer | |
EA201000644A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
NO20082216L (no) | Terapeutisk vaksine | |
EA201790653A1 (ru) | Способ лечения болезни альцгеймера и других расстройств | |
MX2017006663A (es) | Anticuerpos tau humanizados en enfermedad de alzheimer. | |
WO2012106363A3 (en) | Treatment of tauopathies | |
EA201000809A1 (ru) | АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА | |
AR092818A1 (es) | Anticuerpo tau humanizado | |
GB0712160D0 (en) | Methods and compositions in the treatment of procine circoviral infection | |
MX2009003468A (es) | Anticuerpo humanizado contra beta amiloide. | |
EA201201116A1 (ru) | Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а | |
EP2542571A4 (en) | OLIGOMER SPECIFIC BETA AMYLOID EPITOPE AND ANTIBODIES | |
MY164579A (en) | Safe and functional humanized antibodies | |
EA201792447A1 (ru) | Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров | |
EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
PH12014502582A1 (en) | Compounds | |
EA201291040A1 (ru) | Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином | |
CR20140496A (es) | Anticuerpos humanizados contra beta-amiloides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG MD TJ TM |